Details of the Drug Combination

General Information of Drug Combination (ID: DCGW68F)

Drug Combination Name
Heparin Papaverine
Indication
Disease Entry Status REF
Pediatrics Phase 4 [1]
Component Drugs Heparin   DM4ZP3W Papaverine   DMCA9QP
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Heparin
Disease Entry ICD 11 Status REF
Aplastic anemia 3A70 Approved [2]
Bacteremia 1A73 Approved [2]
Burns N.A. Approved [2]
Coronary heart disease BA80.Z Approved [2]
Deep vein thrombosis BD71 Approved [2]
Disseminated intravascular coagulation 3B20 Approved [2]
Metabolic disorder 5C50-5D2Z Approved [2]
Pneumonia CA40 Approved [2]
Pulmonary embolism BB00 Approved [2]
Venous thrombosis BA43 Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [4]
Diabetic angiopathy BD53.Y Investigative [2]
Indication(s) of Papaverine
Disease Entry ICD 11 Status REF
Brain ischaemia 8B1Z Approved [5]
Spasm MB47.3 Approved [6]
Peripheral vascular disease BD4Z Investigative [7]
Papaverine Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Phosphodiesterase 4D (PDE4D) TTSKMI8 PDE4D_HUMAN Inhibitor [8]
Phosphodiesterase 5A (PDE5A) TTJ0IQB PDE5A_HUMAN Inhibitor [9]
------------------------------------------------------------------------------------
Papaverine Interacts with 6 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Transmembrane protease serine 2 (TMPRSS2) OTN44YQ5 TMPS2_HUMAN Increases Expression [10]
Cystic fibrosis transmembrane conductance regulator (CFTR) OT6B22QH CFTR_HUMAN Increases Activity [11]
Hepcidin (HAMP) OT607RBL HEPC_HUMAN Decreases Expression [12]
Heat shock factor protein 1 (HSF1) OTYNJ4KP HSF1_HUMAN Increases Activity [13]
Bile acid receptor (NR1H4) OTWZLPTB NR1H4_HUMAN Increases Activity [14]
Angiotensin-converting enzyme 2 (ACE2) OTTRZGU7 ACE2_HUMAN Decreases Expression [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Pediatrics DCJGS0N N. A. Phase 4 [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03894904) Papaverine vs Heparin for Peripheral Arterial Catheter Patency in Pediatric Patients
2 Heparin FDA Label
3 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 090809.
4 Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020 Dec;9(1):727-732.
5 Intra-Arterial Papaverine-Hydrochloride and Transluminal Balloon Angioplasty for Neurointerventional Management of Delayed-Onset Post-Aneurysmal Subarachnoid Hemorrhage Vasospasm. World Neurosurg. 2018 Nov;119:e301-e312.
6 Drug information of Papaverine, 2008. eduDrugs.
7 Aetiopathogenesis and management of impotence in diabetic males: four years experience from a combined clinic. Diabet Med. 1995 Jan;12(1):77-82.
8 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
9 Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl. 2003 Mar;5(1):15-8.
10 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
11 Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells. Am J Respir Cell Mol Biol. 2003 Sep;29(3 Pt 1):410-8. doi: 10.1165/rcmb.2002-0247OC. Epub 2003 Apr 24.
12 A HAMP promoter bioassay system for identifying chemical compounds that modulate hepcidin expression. Exp Hematol. 2015 May;43(5):404-413.e5. doi: 10.1016/j.exphem.2015.01.005. Epub 2015 Jan 26.
13 A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.
14 Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity. Biochem Pharmacol. 2012 Jun 15;83(12):1674-81. doi: 10.1016/j.bcp.2012.02.027. Epub 2012 Mar 7.